From Lab Discovery to Global Impact: How Kresko RNAtech Is Redefining Wellness Through Science
In an era where innovation often feels incremental, truly groundbreaking ideas tend to emerge at the intersection of disciplines. For Carla Maria Borini Etchetti, the founder of Kresko RNAtech, that intersection lies between molecular biology, nutrition, and real-world impact. Her journey from academic research to building a biotech startup is not just a story of entrepreneurship—it’s a case study in what happens when science refuses to stay confined within laboratory walls.
Kresko RNAtech is not just another wellness company. It represents a new way of thinking about how food, biology, and technology can interact to improve human health. At the core of its innovation is a concept that sounds simple but carries enormous implications: dietary RNAs—naturally occurring molecules found in everyday foods—can influence biological processes in the human body.
The Moment That Changed Everything
Like many scientists, Carla spent years immersed in academic research. She followed the traditional path—earning advanced degrees, publishing papers, contributing to scientific knowledge. But over time, a persistent question began to take shape: What is the real impact of all this work if it never leaves the lab?
The turning point came through a discovery made by her cofounder, Silvana Spinelli. While studying biological systems, Spinelli identified tiny RNA molecules present in breast milk—one of the most biologically complex and essential sources of human nutrition. These molecules weren’t just passive components; they played an active role in regulating health.
Further research, conducted alongside cofounder Uciel Chorostecki, revealed something even more compelling: similar RNA molecules existed in a wide range of foods, including mushrooms, herbs, and so-called “superfoods.”
This discovery reframed how food could be understood—not just as nutrition, but as a form of biological communication.
For Carla, that insight was more than scientific—it was transformative. It became clear that this knowledge had the potential to move beyond research papers and into real-world applications.
That realization marked the beginning of Kresko RNAtech.
Building a Company Without a Blueprint
Transitioning from academia to entrepreneurship is rarely straightforward. In Carla’s case, it meant stepping into a completely unfamiliar world.
There was no background in business, no formal training in startups, and no clear roadmap. What existed instead was a strong scientific foundation and a vision: to translate complex biological discoveries into products that could genuinely improve people’s lives.
The early stages were defined by uncertainty. The team had to answer questions that had nothing to do with lab work:
- Who exactly is the customer?
- What problem are we solving in the market?
- How do we explain RNA technology to non-scientists?
- How do we raise capital and build partnerships?
Rather than seeing these gaps as limitations, the founders approached them the same way they approached science: through learning, iteration, and experimentation.
They joined leading startup accelerators, sought mentorship, and immersed themselves in the business side of innovation. Over time, the team evolved—not just as researchers, but as entrepreneurs capable of building and scaling a company.
The Science Behind Kresko RNAtech
At the heart of Kresko RNAtech is a proprietary platform called Serkanto, which combines artificial intelligence with cellular biology to identify and validate functional RNA molecules.
These dietary RNAs are not synthetic inventions—they already exist in nature. What Kresko does is:
- Identify RNAs with measurable biological effects
- Validate their functionality through scientific testing
- Stabilize them for real-world use
- Integrate them into products across multiple industries
This last step is crucial. Unlike many biotech companies that focus solely on research, Kresko operates as a B2B provider. Its ingredients are designed to be used by other brands in:
- Nutritional supplements
- Functional foods and beverages
- Skincare and cosmetics
The goal is to create a new category of science-backed ingredients that can be seamlessly integrated into everyday products.
Solving the Stability Problem
One of the biggest technical challenges the company faced was also one of the most fundamental: RNA molecules are fragile.
In laboratory conditions, they require strict handling—controlled temperatures, sterile environments, and precise storage methods. But real-world products don’t operate under lab conditions.
If RNA-based ingredients were going to be viable in consumer products, they needed to be:
- Stable at room temperature
- Scalable for production
- Free from harmful solvents or additives
- Able to retain biological activity over time
The solution did not exist—so the team had to create it.
After extensive experimentation, Kresko developed a proprietary, solvent-free stabilization process that preserves RNA functionality while making it practical for industrial use.
This breakthrough transformed the company’s concept into something tangible: a platform capable of delivering real, usable products.
Motivation in a Slow-Moving Industry
Biotech is not a fast industry. Development cycles are long, regulatory requirements are strict, and results often take years to materialize.
For many founders, this pace can be discouraging. For Carla, it became a defining part of the journey.
Motivation, in this context, doesn’t come from quick wins—it comes from purpose.
Kresko is not just building products; it is attempting to redefine how we understand nutrition and health at a molecular level. That long-term vision provides the resilience needed to navigate delays, setbacks, and uncertainty.
Equally important is the team itself. A shared mission creates a culture where progress is measured not just in milestones, but in persistence.
The Funding Challenge
Building a life sciences startup in Argentina adds another layer of complexity.
The local investment ecosystem is still developing, and deep-tech ventures often struggle to secure early-stage funding. Many investors prefer faster returns, making long-term scientific innovation a harder sell.
Kresko’s breakthrough came through strategic support systems.
Programs like GRIDX provided early backing and helped shape the company’s global mindset. Later, participation in IndieBio—one of the world’s leading biotech accelerators—opened doors to international investors and partnerships.
These platforms didn’t just provide funding; they provided credibility, mentorship, and access to a global network.
Real Impact: When Science Becomes Personal
For all the complexity behind the technology, the most meaningful moments are often the simplest.
One of those moments came during early testing of DormoRNA, a sleep-focused ingredient developed by Kresko.
After analyzing feedback from study participants, the team saw something powerful: real people reporting better sleep, reduced stress, and improved quality of life.
At that point, the work stopped being abstract.
It was no longer about molecules or data—it was about impact.
Lessons for Future Female Founders
Carla’s journey offers several clear lessons for women entering technology and entrepreneurship:
- You don’t need to feel ready before you start
- Growth comes from action, not preparation alone
- Asking questions is a strength, not a weakness
- Your perspective is an asset, not something to minimize
Perhaps the most important insight is this: confidence is often the result of movement, not the prerequisite for it.
The Future of Personalized Health
Looking ahead, Kresko RNAtech is positioned within a broader shift toward personalized health and nutrition.
The future is moving beyond generic supplements and one-size-fits-all solutions. Instead, it is heading toward:
- Molecular-level personalization
- Integration of biology and data
- Functional ingredients tailored to individual needs
- Preventative health rather than reactive treatment
Dietary RNAs could play a key role in this transformation, acting as natural regulators of biological processes.
Kresko’s ambition is not just to participate in this shift—but to help define it.
Final Thought
The story of Kresko RNAtech is ultimately about translation.
Not translation between languages, but between worlds—science and society, research and reality, discovery and impact.
It’s a reminder that innovation doesn’t end with a breakthrough. It begins when that breakthrough becomes something people can actually use.
And that step—the hardest one—is where real change happens.
